$IMMP News

Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026

Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?

Immutep Quarterly Activities Report Q3 FY26

Immutep Receives Nasdaq Notice of Bid Price Deficiency

Immutep Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 26 To Regain Compliance

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcoma

Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcoma

FDA Grants Immutep Orphan Drug Designation For Eftilagimod Alfa For Treatment Of Soft Tissue Sarcoma

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases

Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Immustep Independent Data Monitoring Committee Recommends Ending Phase 3 Trial For TACTI-004 Following Planned Futility Analysis

Citizens Downgrades Immutep to Market Perform

Baird Downgrades Immutep to Neutral, Lowers Price Target to $1

Trading Halt: Halt status updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times